

# Drug Policy

<b>Policy:</b>	202002-MRx	<b>Initial Effective Date: 01/16/2020</b>
<b>Code(s):</b>	HCPCS J0223	<b>Annual Review Date: 01/16/2025</b>
<b>SUBJECT:</b>	Givlaari® (givosiran)	<b>Last Revised Date: 01/16/2025</b>

Subject to:  Site of Care  
 Medication Sourcing

**Prior approval is required for some or all procedure codes listed in this Corporate Drug Policy.**

Initial and renewal requests for the medication(s) listed in this policy are subject to site of care management. When billed under the medical benefit, administration of the medication will be restricted to a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) unless the member meets the site of care exception criteria. To view the exception criteria and a list of medications subject to site of care management please [click here](#).

## I. Length of Authorization

Coverage will be provided for 6 months initially and may be renewed annually thereafter.

## II. Dosing Limits

**Max Units (per dose and over time) [HCPS Unit]:**

- 756 billable units every month

## III. Initial Approval Criteria<sup>1</sup>

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

**Universal Criteria** <sup>1,3-7</sup>

- Patient will avoid known triggers of porphyria attacks (i.e., alcohol, smoking, exogenous hormones, hypocaloric diet/fasting, certain medications such as barbiturates, hydantoin, sulfa-antibiotics, anti-epileptics, etc.); **AND**
- Patient has not had or is not anticipating a liver transplant; **AND**

**Acute Hepatic Porphyria (AHP) † Φ** <sup>1,3-5,7</sup>

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

# Drug Policy

- Patient has a definitive diagnosis of acute hepatic porphyria\* (including acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, or ALA dehydratase deficient porphyria) as evidenced by one of the following:
  - Patient has had elevated urinary or plasma PBG (porphobilinogen) and ALA (delta-aminolevulinic acid) levels within the previous year; **OR**
  - Patient has a mutation in an affected gene as identified on molecular genetic testing; **AND**
- Patient has a history of at least two documented porphyria attacks (i.e., requirement of hospitalization, urgent healthcare visit or intravenous administration of hemin) **OR** one severe attack with CNS involvement (e.g., hallucinations, seizures, etc.) during the previous six months; **AND**
- Patients currently receiving prophylactic intravenous hemin therapy will discontinue hemin within 3 to 6 months following initiation of givosiran

*Acute Hepatic Porphyria	Urine delta-aminolevulinic acid (ALA)	Urine porphobilinogen (PBG)	Urine porphyrins	Gene
Acute Intermittent Porphyria (AIP)	Elevated	Elevated	Increased uroporphyrin	<i>HMBS</i>
Hereditary Coproporphyria (HCP)	Elevated	Elevated	Increased coproporphyrin	<i>CPOX</i>
Variegate Porphyria (VP)	Elevated	Elevated	Increased coproporphyrin	<i>PPOX</i>
ALA Dehydratase-Deficiency Porphyria (ADP)	Elevated	Normal	Increased coproporphyrin	<i>ALAD</i>

† FDA Approved Indication(s); ‡ Compendium Recommended Indication(s); Ⓢ Orphan Drug

## IV. Renewal Criteria <sup>1</sup>

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: anaphylactic reactions, severe hepatic toxicity, severe renal toxicity, severe injection site reactions, increase in blood homocysteine levels, acute pancreatitis, etc.; **AND**
- Disease response as evidenced by a decrease in the frequency of acute porphyria attacks, and/or hospitalizations/urgent care visits, and/or a decrease requirement of hemin intravenous infusions for acute attacks; **AND**

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

# Drug Policy

- Patient has a reduction/normalization of biochemical markers (i.e., ALA, PBG) compared to baseline; **AND**
- Patient will not use in combination with prophylactic intravenous hemin therapy

## V. Dosage/Administration <sup>1</sup>

Indication	Dose
Acute Hepatic Porphyria (AHP)	<p><b>For administration by a healthcare professional as a subcutaneous injection only.</b></p> <ul style="list-style-type: none"> <li>• Administer 2.5 mg/kg via subcutaneous injection once monthly. Dosing is based on actual body weight.</li> </ul>

## VI. Billing Code/Availability Information

### HCPCS Code:

- J0223 – Injection, givosiran, 0.5 mg: 1 billable unit = 0.5 mg

### NDC:

- Givlaari 189 mg/mL in a single-dose vial for injection: 71336-1001-xx

## VII. References

1. Givlaari [package insert]. Cambridge, MA; Alnylam Pharm., Inc., April 2024. Accessed December 2024.
2. Sardh E, Barbaro M. Acute Intermittent Porphyria. 2005 Sep 27 [Updated 2024 Feb 8]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1193/>
3. Anderson KE. Porphyrias: An overview. In: Means RT, Tirnauer JS (Eds), *UpToDate*. Last updated: August 05, 2024. Accessed on December 02, 2024. [https://www.uptodate.com/contents/porphyrias-an-overview?search=Porphyrias:%20An%20overview&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/porphyrias-an-overview?search=Porphyrias:%20An%20overview&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1).
4. Balwani M, Gouya L, Rees D, et al. GS-14-ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients. *J Hepatology*:Apr 2019; Vol 70; Iss. 1, Suppl;pps e81–e82
5. Balwani M, Sardh E, Ventura P, et al.; ENVISION Investigators. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. *N Engl J Med*. 2020 Jun 11;382(24):2289-2301.
6. Balwani M, Wang B, Anderson KE. Acute hepatic porphyrias: Recommendations for evaluation and long-term management. *Hepatology*. Volume66, Issue4 October 2017. Pages 1314-1322. <https://doi.org/10.1002/hep.29313>
7. Wang B, Bonkovsky HL, Kim, JK, et al. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. *Gastroenterology*. Volume 164, Issue 3, Pages 484-491. [https://www.gastrojournal.org/article/S0016-5085\(22\)01356-7/fulltext](https://www.gastrojournal.org/article/S0016-5085(22)01356-7/fulltext)

# Drug Policy

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
E80.20	Unspecified porphyria
E80.21	Acute intermittent (hepatic) porphyria
E80.29	Other porphyria

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT,	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

# Drug Policy

**FOR MEDICAL BENEFIT COVERAGE REQUESTS:**

**Prior approval is required for HCPCS Codes J0223**

**†When J0223 is determined to be Givlaari**